Aclaris Therapeutics, Inc. said the US Patent and Trademark Office (USPTO) issued two patents “directed to methods related to the use and administration of certain janus kinase (JAK) inhibitors for treating hair loss disorders.”
Aclaris said the newly allowed patents are owned by The Trustees of Columbia University in New York and exclusively licensed to Aclaris, and are the latest US patents to issue in connection with Aclaris’ JAK drug development program for hair loss disorders.
Aclaris CEO Neal Walker said: “We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia.
“These new issuances continue to expand the breadth and depth of our JAK inhibitor intellectual property portfolio covering methods of use for certain JAK inhibitors for the treatment of hair loss disorders.
“The issuance of these patents is another successful step in the development of a robust patent portfolio relating to JAK inhibition and hair loss.”